Key terms
About NKTR
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NKTR news
Apr 05
10:40am ET
Biotech Alert: Searches spiking for these stocks today
Mar 07
4:55am ET
Nektar management to meet with Oppenheimer
Mar 07
1:00am ET
Nektar Therapeutics Is Worried About This – Should You Be Worried Too?
Mar 06
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Mar 05
9:40pm ET
Nektar management to meet with Oppenheimer
Mar 05
9:09am ET
Nektar initiates Phase 2b clinical study of alopecia areata candidate
Mar 04
4:16pm ET
Nektar reports Q4 EPS (22c), consensus (21c)
Mar 04
3:11pm ET
Nektar options imply 26.2% move in share price post-earnings
Mar 04
8:41am ET
Nektar sells 25M shares at $1.20 in private placement
Mar 04
7:36am ET
Y-mAbs Therapeutics appoints Tagliaferri to board of directors
No recent press releases are available for NKTR
NKTR Financials
Key terms
Ad Feedback
NKTR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NKTR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range